Prof. Luca Malcovati – Biosketch

Personal data		
Name:	Luca Malcovati	
Date and place of birth:	16/05/1972, Milano, Italy	
Citizenship:	Italian	
Current work address:	Department of Molecular Medicine, University of Pavia & Department of Hematology Oncology, IRCCS S. Matteo Hospital Foundation P.le Golgi 2, 27100 Pavia, Italy	

Luca Malcovati is Associate Professor of Hematology at the Department of Molecular Medicine, University of Pavia, Medical School, and consultant physician at the Department of Hematology Oncology, Chair of the Unit of Precision Hematology-Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.

Luca Malcovati's research activity has been mainly focused on the study of myeloid neoplasms, and particularly of myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and secondary acute myeloid leukemias (MDS/AML). His work focused on the prognosis of MDS, and allowed to identify new prognostic factors, and to develop new prognostic scoring systems in MDS and MDS/MPN. Prof. Malcovati's research also dealt on the study molecular basis of MDS and MDS/MPN. He made a significant contribution to identify acquired mutations in splicing factors in myeloid neoplasms, to determine the clinical and biological implications of driver mutations in these disorders, and to identify genetically-defined disease entities. More recently, he focused on myeloid pre-malignant conditions, including clonal hematopoiesis (CH), clonal cytopenia of undetermined significance (CCUS) and clonal monocytosis. On behalf of the European LeukemiaNet and the European Hematology Association, he coordinated the development of international evidence-based recommendations for diagnosis and treatment of MDS and for chronic myelomonocytic leukemia. His research activity resulted in 201 papers published in peer-reviewed journals with total Impact Factor of 2560.772, and H index of 71.

Luca Malcovati has been member of the WHO Classification of Haematopoietic and Lymphoid Tumors Clinical Advisory Committee, the International Working Group for MDS and MDS/MPN (IWG-PM, IWG-MD/MPN), the Myeloid Malignancies Expert Panel of Clinical Genome Program (ClinGen), the Board of Directors of the Myelodysplastic Syndromes International Foundation, the Scientific and Strategic Board of the European Reference Network for Rare Hematologic Diseases (EuroBloodNet), the Steering Committee of the European Registry of Myelodysplastic Syndromes. He served as Editor-in-Chief of Haematologica from 2017 to 2021 and as a member of the Board of the European Hematology Association from 2011 to 2015.